The global oral proteins and peptides market is experiencing explosive growth as pharmaceutical innovation converges with rising patient demand for non-invasive treatment alternatives. New industry research values the market at USD 6,350.0 million in 2023, with growth projected to USD 7,462.0 million in 2024 and a striking USD 26,936.2 million by 2031, representing a CAGR of 20.13% during the forecast period, among the fastest growth rates of any pharmaceutical delivery segment.
Redefining Biologic Drug Delivery
Oral proteins and peptides are biologically active macromolecules made of amino acids, used for therapeutic and nutritional purposes across conditions including diabetes, cancer, and hormonal imbalances. The market covers development, production, and commercialization of these molecules, including therapeutic proteins such as insulin and growth factors, alongside nutritional supplements. Advances in formulation and drug delivery are steadily improving their stability and bioavailability, addressing historic limitations that once confined such therapies to injectable formats.
Patient Preference Drives the Shift From Injectables
The shift toward patient-friendly, non-invasive drug administration is fundamentally reshaping the market. Oral formulations provide a convenient alternative to injectable drugs, improving patient compliance and treatment outcomes, particularly significant among elderly patients and those requiring frequent drug administration for chronic conditions such as diabetes, gastrointestinal disorders, and hormonal imbalances. The growing global diabetic population and expanding geriatric demographic, which requires long-term, convenient treatment options, are further amplifying demand.
Pharmaceutical companies are investing heavily in overcoming the technical barriers that traditionally limited oral biologics. Innovations including nanoparticle carriers, permeation enhancers, and enzyme inhibitors are addressing the historic challenges of enzymatic degradation in the gastrointestinal tract and poor intestinal permeability. In September 2024, Vivtex Corporation and Equillium announced a research and licensing agreement to develop an optimized oral formulation of EQ302, a bi-specific peptide inhibitor targeting gastrointestinal inflammation, leveraging Vivtex’s proprietary AI-enabled GI-ORIS screening and formulation technology to enhance oral bioavailability.
Bioavailability Remains the Central Technical Challenge
Despite rapid growth, the market continues to grapple with fundamental bioavailability and stability challenges. Oral proteins and peptides are highly susceptible to breakdown by digestive enzymes such as pepsin, trypsin, and chymotrypsin, which rapidly degrade them before they can reach systemic circulation. Their large molecular size and hydrophilic nature further limit permeability across the intestinal epithelium. Pharmaceutical companies are responding with advanced delivery systems, including enzyme inhibitors, permeation enhancers, and nanoparticle-based carriers designed to protect drugs from degradation and improve absorption.
High production costs and complex manufacturing processes present an additional hurdle. Unlike conventional small-molecule drugs, these biologics require specialized formulation techniques to maintain stability, and large-scale production and storage demand stringent conditions that add to overall expense. Companies are investing in novel formulation technologies and cost-effective manufacturing approaches, including recombinant DNA technology and bioengineered delivery systems, to improve efficiency and scalability.
Research Pipeline Expands Rapidly
Rising investment in research and development is fueling an expanding pipeline of advanced therapeutics. Pharmaceutical companies and biotech firms are developing novel oral peptide formulations leveraging lipid-based carriers, permeation enhancers, and enzyme inhibitors, with increasing clinical trials, regulatory approvals, and strategic collaborations bringing new treatments to market. In July 2024, Pfizer announced advancement of a once-daily formulation of oral GLP-1 receptor agonist danuglipron, selecting a preferred modified-release version for further dose optimization studies targeting obesity and blood sugar control, seeking a competitive position in the oral GLP-1 market.
Segment-Level Insights
By drug type, linaclotide generated the highest revenue in 2023 at USD 2,527.7 million, driven by its effectiveness in managing gastrointestinal disorders and growing adoption in prescription treatments. It is projected to remain the dominant segment, reaching USD 11,366.6 million by 2031. By application, diabetes accounted for 34.14% of the market in 2023, reflecting the rising global diabetic population and advancements in oral peptide-based drug formulations, with the segment projected to reach USD 10,010.4 million by 2031.
Regional Landscape
North America led the global market in 2023 with a 36.62% share valued at USD 2,325.4 million, driven by the strong presence of leading pharmaceutical and biotechnology companies investing heavily in oral protein and peptide research. The region benefits from high healthcare expenditure, well-established regulatory frameworks, and favorable reimbursement policies that support adoption of innovative biologics, alongside expanding clinical trials and FDA approvals for novel oral biologics.
Asia Pacific is set to register the fastest growth, with a projected CAGR of 21.33% through 2031, reaching a projected value of USD 6,085.3 million. This growth is fueled by increasing healthcare investments, expanding pharmaceutical manufacturing capabilities, and the growing burden of chronic diseases including diabetes, osteoporosis, and hormonal disorders across China, India, and Japan. Government initiatives supporting biopharmaceutical research and a growing number of clinical trials and regulatory approvals are accelerating adoption, alongside rising disposable incomes and greater awareness of advanced treatment options.
Regulatory Environment
In the United States, the FDA regulates oral proteins and peptides under the Biologics Control Act and the Federal Food, Drug, and Cosmetic Act, requiring rigorous clinical trials to confirm safety, efficacy, and bioavailability before approval. In Europe, the European Medicines Agency oversees approval through its Committee for Medicinal Products for Human Use, requiring compliance with Good Manufacturing Practices and extensive clinical evaluation. China’s National Medical Products Administration regulates such drugs under the Drug Administration Law, with a regulatory framework strengthened to align with international standards, while Japan’s Pharmaceuticals and Medical Devices Agency requires extensive pharmacokinetic and bioequivalence studies. India’s Central Drugs Standard Control Organization regulates the sector through the New Drugs and Clinical Trials Rules.
Competitive Landscape
The market features both established pharmaceutical giants and emerging biotech firms, including Novo Nordisk A/S, AbbVie Inc., Pfizer Inc., Biocon Limited, Groupe Sanofi, Oramed Pharmaceuticals Inc, Johnson & Johnson Services, Inc., EnteraBio Ltd., Chiesi Farmaceutici S.p.A., Proxima Concepts, Tarsa Therapeutics, Inc., and Synergy Pharma. In February 2025, Oramed Pharmaceuticals and Hefei Tianhui Biotech announced a transformative joint venture, OraTech Pharmaceuticals, to accelerate development and commercialization of oral insulin using Oramed’s Protein Oral Delivery technology. In December 2024, AbbVie announced the acquisition of Nimble Therapeutics, gaining an investigational oral peptide inhibitor for psoriasis and a broader pipeline of oral peptide candidates for autoimmune diseases, along with Nimble’s proprietary peptide synthesis platform.
Outlook
With a projected CAGR of 20.13%, one of the highest growth rates in the pharmaceutical industry, the oral proteins and peptides market stands at the forefront of the shift toward patient-centric biologic therapy. As formulation technologies continue maturing and address longstanding bioavailability constraints, oral delivery is poised to displace a meaningful share of the injectable biologics market over the coming decade, reshaping treatment paradigms for diabetes, gastrointestinal disorders, and beyond.
